Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which missed the analyst consensus estimate of $(1.02) by 18.63 percent. This is a 133.43 percent decrease over earnings of $3.62 per share from the same period last year. The company reported quarterly sales of $367.000 thousand which missed the analyst consensus estimate of $583.333 thousand by 37.09 percent. This is a 99.83 percent decrease over sales of $211.246 million the same period last year.